Baxter(US:BAX)2025-02-20 19:46Financial Performance - Worldwide Baxter sales from continuing operations grew 1% on a reported basis and 2% on a constant currency basis[13] - Adjusted earnings per share from continuing operations totaled $058, exceeding the company's original guidance of $050 to $053 per diluted share[13] - Full-Year 2024 global reported sales were $106 billion, a 3% increase compared to FY 2023[22] - Full-Year 2024 adjusted diluted EPS was $189, an 11% increase compared to FY 2023[22] - Q4 2024 adjusted operating margin was 152%, a decrease of 190 bps year-over-year[19] Business Operations and Strategy - Baxter completed the sale of its Kidney Care business to Carlyle on January 31, 2025 for approximately $34 billion of net, after-tax proceeds[13] - Hurricane Helene negatively impacted sales by approximately $110 million in Q4 2024[13] - Baxter's North Cove manufacturing site has restarted all 10 manufacturing lines and is producing at pre-hurricane levels[13] - Baxter paid a quarterly dividend of $017 per share, reflecting a commitment to return value to shareholders[16, 31] 2025 Outlook - The company projects Q1 2025 sales growth of 3%-4% and adjusted diluted EPS from continuing operations of $047-$050[46] - The company projects FY 2025 sales growth of 5%-6% and adjusted diluted EPS from continuing operations of $245-$255[47]